<?xml version="1.0" encoding="UTF-8"?>
<p>The approved maximum dose of febuxostat in Japan is 60 mg once a day. In this study, 20 mg of febuxostat and 500 mg of Ino were administered twice a day after breakfast and dinner. That modification was made based on previous pharmacokinetic/pharmacodynamic data
 <sup>[
  <xref rid="R44" ref-type="bibr">44</xref>]
 </sup> and had the goal of maintaining high blood levels of Hyp and ATP throughout the day. The 8 weeks administration period was deemed a sufficient period to evaluate efficacy and safety in an early-stage clinical trial of PD. It was expected to be sufficient to evaluate the symptomatic improvement of the disease although not sufficient to evaluate the disease-modifying effect.
 <sup>[
  <xref rid="R45" ref-type="bibr">45</xref>]
 </sup>
</p>
